ZAFIRLUKAST Drug Patent Profile
✉ Email this page to a colleague
When do Zafirlukast patents expire, and what generic alternatives are available?
Zafirlukast is a drug marketed by Annora Pharma, Aurobindo Pharma, Dr Reddys Labs Ltd, and Rising Pharms. and is included in four NDAs.
The generic ingredient in ZAFIRLUKAST is zafirlukast. There are four drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the zafirlukast profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zafirlukast
A generic version of ZAFIRLUKAST was approved as zafirlukast by DR REDDYS LABS LTD on November 18th, 2010.
Summary for ZAFIRLUKAST
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 6 |
Patent Applications: | 4,102 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZAFIRLUKAST |
What excipients (inactive ingredients) are in ZAFIRLUKAST? | ZAFIRLUKAST excipients list |
DailyMed Link: | ZAFIRLUKAST at DailyMed |
Recent Clinical Trials for ZAFIRLUKAST
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
King Abdullah International Medical Research Center | Phase 3 |
National Institutes of Health (NIH) | Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Pharmacology for ZAFIRLUKAST
Drug Class | Leukotriene Receptor Antagonist |
Mechanism of Action | Cytochrome P450 2C9 Inhibitors Leukotriene Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ZAFIRLUKAST
Paragraph IV (Patent) Challenges for ZAFIRLUKAST
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ACCOLATE | Tablets | zafirlukast | 10 mg and 20 mg | 020547 | 1 | 2008-02-29 |